John Hussman's ARWR Position Overview
John Hussman (via Hussman Strategic Advisors, Inc.) currently holds 21,000 shares of Arrowhead Pharmaceuticals, Inc. (ARWR) worth $1.71 M, representing 0.39% of the portfolio. First purchased in 2018-Q4, this short-term holding has been held for 7 quarters.
Based on 13F filings, John Hussman has maintained this position in ARWR for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2020, adding 62,000 shares. Largest reduction occurred in Q1 2019, reducing 50,000 shares.
Analysis based on 13F filings available since 2013 Q2
John Hussman's Arrowhead Pharmaceuticals (ARWR) Holding Value Over Time
Track share changes against reported price movement
Quarterly Arrowhead Pharmaceuticals (ARWR) Trades by John Hussman
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +21,000 | New Buy | 21,000 | $81.51 |
| Q4 2020 | -25,500 | Sold Out | 0 | $0.00 |
| Q3 2020 | -36,000 | Reduce 58.54% | 25,500 | $43.06 |
| Q2 2020 | -500 | Reduce 0.81% | 61,500 | $43.19 |
| Q1 2020 | +62,000 | New Buy | 62,000 | $28.77 |
| Q1 2019 | -50,000 | Sold Out | 0 | $0.00 |
| Q4 2018 | +50,000 | New Buy | 50,000 | $12.42 |
John Hussman's Arrowhead Pharmaceuticals Investment FAQs
John Hussman first purchased Arrowhead Pharmaceuticals, Inc. (ARWR) in Q4 2018, acquiring 50,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman has held Arrowhead Pharmaceuticals, Inc. (ARWR) for 7 quarters since Q4 2018.
John Hussman's largest addition to Arrowhead Pharmaceuticals, Inc. (ARWR) was in Q1 2020, adding 62,000 shares worth $1.78 M.
According to the latest 13F filing for Q2 2026, John Hussman's firm, Hussman Strategic Advisors, Inc., owns 21,000 shares of Arrowhead Pharmaceuticals, Inc. (ARWR), valued at approximately $1.71 M.
As of the Q2 2026 filing, Arrowhead Pharmaceuticals, Inc. (ARWR) represents approximately 0.39% of John Hussman's publicly disclosed stock portfolio, making it one of their key holdings.
John Hussman's peak holding in Arrowhead Pharmaceuticals, Inc. (ARWR) was 62,000 shares, as reported at the end of Q1 2020.